Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets

Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets

Tremendous progress has been made to control the COVID-19 pandemic caused by the SARS-CoV-2 virus. However, effective therapeutic options are still rare. Drug repurposing and combination represent practical strategies to address this urgent unmet medical need. Viruses, including coronaviruses, are k...

Full description

Bibliographic Details
Main Authors: Chanda, S.K (Author), Cheng, K. (Author), Martin-Sancho, L. (Author), Nair, N.U (Author), Pal, L.R (Author), Pu, Y. (Author), Riva, L. (Author), Ruppin, E. (Author), Sinha, S. (Author), Yin, X. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
Adenosine Monophosphate
adenosine phosphate
alanine
Alanine
animal
Animals
Antiviral Agents
antiviral target
antivirus agent
Caco-2 cell line
Caco-2 Cells
Chlorocebus aethiops
COVID-19
Datasets as Topic
drug development
Drug Development
drug repositioning
Drug Repositioning
drug therapy
genetics
genome-scale metabolic modeling
host pathogen interaction
Host-Pathogen Interactions
human
Humans
information processing
meta analysis
Metabolic Networks and Pathways
metabolism
pandemic
Pandemics
physiology
remdesivir
RNA, Small Interfering
RNAi screen
SARS-CoV-2
sequence analysis
Sequence Analysis, RNA
small interfering RNA
Vero cell line
Vero Cells
virology
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items